Form 4: Cencora Officer Reports RSU Vesting, Share Transactions

Cencora's SVP & Chief Accounting Officer, Lazarus Krikorian, reported the vesting of restricted stock units and subsequent share transactions for tax withholding.

Summary

• Lazarus Krikorian, SVP & Chief Accounting Officer of Cencora, Inc. (COR), reported changes in his beneficial ownership.
• On November 7, 2025, Krikorian acquired 1,433 shares of common stock due to the vesting of restricted stock units (RSUs).
• These RSUs were part of a grant that vests in three equal annual installments on November 9, 2023, November 9, 2024, and November 9, 2025.
• Concurrently, 411 shares were disposed of at $360.7 per share to cover tax withholding obligations related to this vesting.
• Also on November 7, 2025, Krikorian acquired an additional 1,398 shares of common stock from another RSU grant.
• This second RSU grant vests in three equal installments on November 8, 2024, November 8, 2025, and November 8, 2026.
• An additional 366 shares were disposed of at $360.7 per share for tax withholding related to this second vesting event.
• Following these transactions, Krikorian directly owns 19,208 shares of Cencora common stock and 1,398 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It reports routine executive compensation events (RSU vesting) which are generally positive as they align executive interests with shareholders. The share dispositions are for tax purposes, a standard practice, and not indicative of a negative outlook.

Positives

• Vesting of restricted stock units indicates continued long-term incentive alignment between management and shareholders.
• The officer's beneficial ownership of common stock remains substantial at 19,208 shares, demonstrating ongoing stake in the company.

Negatives

• Disposition of shares for tax withholding purposes reduces the officer's direct shareholding, though this is a standard practice for RSU vesting.

Future Outlook

The filing primarily reports past and current transactions related to executive compensation. It implicitly indicates future vesting events for a portion of the officer's restricted stock units, with the next installment due on November 8, 2026.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects standard executive compensation practices involving restricted stock units and subsequent tax-related share dispositions. It does not provide specific insights into broader industry trends for the pharmaceutical or healthcare distribution sector where Cencora operates, but rather details an individual executive's equity movements.

Comparison to Industry Standards

• The RSU vesting and subsequent share sales for tax purposes are standard practices for executive compensation across various industries, including healthcare distribution.
• Companies like Cardinal Health (CAH) and McKesson (MCK), Cencora's peers, also utilize similar equity compensation structures for their executives, leading to comparable Form 4 filings when RSUs vest.
• The reported transactions align with typical executive equity management strategies.

Stakeholder Impact

• Shareholders: The vesting of RSUs and subsequent share sales for tax purposes are routine and expected. They slightly increase the float but are generally seen as a positive for aligning executive incentives.
• Management: Lazarus Krikorian's equity stake in Cencora remains significant, reinforcing his alignment with company performance.

Next Steps

• Future vesting of 1,398 Restricted Stock Units, with the next installment on November 8, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related share dispositions) and does not contain any new material information that would fundamentally alter the investment thesis for Cencora. The transactions are standard and expected, thus warranting a 'hold' recommendation based solely on this filing, as it provides no new catalysts for a 'buy' or 'sell' decision.

Keywords

Cencora, COR, Lazarus Krikorian, SVP & Chief Accounting Officer, Restricted Stock Units, RSU vesting, Insider Trading, Beneficial Ownership, Executive Compensation, Share Transactions, SEC Form 4